Literature DB >> 3204106

Blood histamine and solid malignant tumors.

C M Moriarty1, J L Stucky, K W Hamburger, K D Patil, J F Foley, R R Koefoot.   

Abstract

A clinical study was performed to determine whether patients with a newly diagnosed solid malignant tumor manifest an alteration in whole-blood histamine levels. Our results indicate that such patients have blood histamine nearly three times greater than either normal, healthy individuals or noncancerous disease controls. Following surgical removal of the tumor, blood histamine levels remained high for 2 months and then dropped close to the normal range 3 months after surgery. Basophil counts did not change significantly in the presence of a malignant tumor. Patients receiving either chemotherapy or radiation therapy, and terminal cancer patients who were no longer receiving any therapy except for pain control had blood histamine within or below the normal range. By analogy with animals studies, we suggest that nascent histamine synthesis is increased in the presence of a developing tumor. The clinical usefullness of this observation remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3204106     DOI: 10.1007/bf00398182

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  25 in total

1.  Increased sensitivity of the enzymatic isotopic assay of histamine: measurement of histamine in plasma and serum.

Authors:  R E Shaff; M A Beaven
Journal:  Anal Biochem       Date:  1979-04-15       Impact factor: 3.365

2.  The absolute peripheral basophil count. A new and more precise method.

Authors:  S R Hirsch; A A Rimm; J E Zastrow
Journal:  J Allergy Clin Immunol       Date:  1974-05       Impact factor: 10.793

3.  A study on the induction of histidine decarboxylase in tumor-bearing rat.

Authors:  E Ishikawa; A Toki; T Moriyama; Y Matsuoka; T Aikawa; M Suda
Journal:  J Biochem       Date:  1970-09       Impact factor: 3.387

4.  The demonstration of histamine release in clinical conditions: a review of past and present assay procedures.

Authors:  M A Beaven; A Robinson-White; N B Roderick; G L Kauffman
Journal:  Klin Wochenschr       Date:  1982-09-01

5.  Tumour-associated inhibition of immediate hypersensitivity reactions in mice.

Authors:  N R Lynch; J C Salomon
Journal:  Immunology       Date:  1977-05       Impact factor: 7.397

6.  Involvement of histamine in growth of mouse and rat tumors: antitumoral properties of monofluoromethylhistidine, an enzyme-activated irreversible inhibitor of histidine decarboxylase.

Authors:  J Bartholeyns; M Bouclier
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

7.  Increase in histidine decarboxylase activity in skin of genetically mast-cell-deficient W/Wv mice after application of phorbol 12-myristate 13-acetate: evidence for the presence of histamine-producing cells without basophilic granules.

Authors:  Y Taguchi; K Tsuyama; T Watanabe; H Wada; Y Kitamura
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

8.  Histamine levels in blood and other tissues of male and female C3H mice. II. Mice carrying a 3-methyl-cholanthrene-induced tumor [proceedings].

Authors:  P Scheinmann; B Lebel; N R Lynch; J C Salomon; J R Paupe; C Burtin
Journal:  Agents Actions       Date:  1979-04

9.  Decreased skin response to intradermal histamine in cancer patients.

Authors:  C Burtin; C Noirot; C Giroux; P Scheinmann
Journal:  J Allergy Clin Immunol       Date:  1986-07       Impact factor: 10.793

10.  Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors.

Authors:  C Burtin; P Scheinmann; J C Salomon; G Lespinats; P Canu
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

View more
  4 in total

Review 1.  The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer.

Authors:  P Uotila
Journal:  Cancer Immunol Immunother       Date:  1996-09       Impact factor: 6.968

2.  The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1.

Authors:  Hongzhong Li; Yi Xiao; Qin Li; Jun Yao; Xiangliang Yuan; Yuan Zhang; Xuedong Yin; Yohei Saito; Huihui Fan; Ping Li; Wen-Ling Kuo; Angela Halpin; Don L Gibbons; Hideo Yagita; Zhongming Zhao; Da Pang; Guosheng Ren; Cassian Yee; J Jack Lee; Dihua Yu
Journal:  Cancer Cell       Date:  2021-11-24       Impact factor: 31.743

3.  Apigenin Inhibits the Histamine-Induced Proliferation of Ovarian Cancer Cells by Downregulating ERα/ERβ Expression.

Authors:  Manman Liu; Yani Zhang; Qiqi Xu; Guirong Liu; Na Sun; Huilian Che; Tao He
Journal:  Front Oncol       Date:  2021-09-08       Impact factor: 6.244

4.  Malignant melanoma in a grey horse: case presentation and review of equine melanoma treatment options.

Authors:  Lucy Va Metcalfe; Peter J O'Brien; Stratos Papakonstantinou; Stephen D Cahalan; Hester McAllister; Vivienne E Duggan
Journal:  Ir Vet J       Date:  2013-11-06       Impact factor: 2.146

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.